Source: https://slphealthcareupdate.com/2017/09/
Timestamp: 2019-04-21 07:06:05+00:00

Document:
Pharmaceutical Manufacturer Novo Nordisk Inc.’s $58.65 million settlement resolving charges it failed to comply with the Federal Drug Administration (FDA)-mandated Risk Evaluation and Mitigation Strategy (REMS) for its Type II diabetes medication Victoza illustrates the potential consequences that pharmaceutical companies risk by failing to provide FDA-required warnings about potential side effects of their drugs.
The settlement announced by the Department of Justice (DOJ) on September 5, 2017 resolves a DOJ civil complaint filed September 5, 2017 charging that Novo Nordisk violated a FDA requirement in effect at the time of Victoza’s approval in 2010 that Novo Nordisk provide information regarding Victoza’s potential risk of MTC to physicians. The FDA required the notice to mitigate the potential risk in humans of a rare form of cancer called Medullary Thyroid Carcinoma (MTC) associated with the drug. DOJ charged that some Novo Nordisk sales representatives gave information to physicians that created the false or misleading impression that the Victoza REMS-required message was erroneous, irrelevant, or unimportant. The complaint also alleges that Novo Nordisk failed to comply with the REMS by creating the false or misleading impression about the Victoza REMS-required risk message that violated provisions of the FDCA and led some physicians to be unaware of the potential risks when prescribing Victoza.
According to the government’s complaint, after a survey in 2011 showed that half of primary care doctors polled were unaware of the potential risk of MTC associated with the drug, the FDA required a modification to the REMS to increase awareness of the potential risk. Rather than appropriately implementing the modification, the complaint claims that Novo Nordisk instructed its sales force to provide statements to doctors that obscured the risk information and failed to comply with the REMS modification. Novo Nordisk has agreed to disgorge $12.15 million in profits derived from its unlawful conduct in violation of the FDCA.
A manufacturer that fails to comply with the requirements of the REMS, including requirements to communicate accurate risk information, renders the drug misbranded under the FDCA.
Under the agreed settlement, Novo Nordisk will pay an additional $46.5 million to the federal government and the states to resolve claims under the FCA and state false claims acts. This portion of the settlement resolves allegations that Novo Nordisk caused the submission of false claims from 2010 to 2014 to federal health care programs for Victoza by arming its sales force with messages that could create a false or misleading impression with physicians that the Victoza REMS-required message about the potential risk of MTC associated with Victoza was erroneous, irrelevant, or unimportant and by encouraging the sale to and use of Victoza by adult patients who did not have Type II diabetes. The Food and Drug Administration (FDA) has not approved Victoza as safe and effective for use by adult patients who do not have Type II diabetes. As a result of the FCA settlement, the federal government will receive $43,129,026 and state Medicaid programs will receive $3,320,963.
The FCA settlement also resolves seven lawsuits filed under the whistleblower provision of the federal FCA, which permits private parties to file suit on behalf of the United States for false claims and share in a portion of the government’s recovery. The civil lawsuits are captioned as follows: United States, et al. ex rel. Kennedy, v. Novo A/S, et al., No. 13-cv-01529 (D.D.C.), United States, et al. ex rel. Dastous, et al. v. Novo Nordisk, No. 11-cv-01662 (D.D.C), United States, et al., ex rel. Ferrara and Kelling v Novo Nordisk, Inc., et al., No. 1:11-cv-00074 (D.D.C.), United States, et al., ex rel. Myers v. Novo Nordisk, Inc., No. 11-cv-1596 (D.D.C.), United States, et al. ex rel Stepe v. Novo Nordisk, Inc., No. 13-cv-221 (D.D.C.), United States et al. ex rel Doe, et al. v. Novo Nordisk, Inc., et al., No. 1:17-00791 (D.D.C.), and United States ex rel. Smith, et al. v. Novo Nordisk, Inc., Civ. Action No. 16-1605 (D.D.C.). The amount to be recovered by the private parties has not been determined.
The U.S. Department of Health and Human Services (HHS), Office for Civil Rights (OCR) has entered into a Voluntary Resolution Agreement with Heritage Hills Living & Rehabilitation Center, LLC (Heritage Hills) that resolves a HHS complaint alleging that Heritage Hills discharged a seriously ill patient from its facility upon learning that she was HIV positive and in violation of Section 504 of the Rehabilitation Act of 1973 and Section 1557 of the Affordable Care Act. Part of HHS’ expanding civil rights enforcement emphasis, the resolution agreement reminds health care providers and others receiving or providing services funded by programs managed by HHS of their growing exposure to civil rights prosecutions and liability for failing to comply with federal civil rights law nondiscrimination rules.
Heritage Hills is a for-profit, 81-bed, certified skilled nursing facility located in the City of McAlester, in Pittsburg County, Oklahoma. Because Heritage Hills receives Federal financial assistance through its participation in the Medicare and Medicaid programs, it is subject to the requirements of Section 504 and Section 1557.
Heritage Hills agreed to resolve the complaint after OCR initiated an investigation into whether Heritage Hills discriminated against the complainant’s daughter on the basis of the daughter’s disability (HIV/AIDS) in violation of Section 504 and Section 1557.
Rrevise its admissions policy to ensure that all individuals with disabilities, including but not limited to HIV/AIDS, are provided equal access to and an equal opportunity to participate in all programs, benefits and services offered by the facility.
The HHS enforcement action reminds health care providers about the importance of properly managing their civil rights compliance. During the last five years, OCR has engaged in more than 200 enforcement and outreach efforts involving HIV/AIDS, including public education campaigns, HIV-related civil rights complaint investigations, HIV-related health information privacy investigations and 12 joint civil rights/health information privacy compliance reviews, which were the subject of OCR’s report, Protecting the Civil Rights and Health Information Privacy of People Living with HIV/AIDS. The report is available here.
Of particular note, OCR has launched an Information is Powerful Medicine public education campaign, which encourages those living with HIV to be proactive in their health care. The campaign explains individuals’ health information privacy rights, including how individuals can monitor and access a copy of their medical records.
OCR’s enforcement in this and other HIV discrimination actions is part a broader nondiscrimination and civil rights enforcement initiative under Section 1551 and other federal laws which has resulted in a growing list of multi-million dollar settlements from health care providers, state and local government agencies and others receiving federal funding from programs managed by the Department of Health & Human Services. See here. Health care providers should verify their policies and operations comply with these civil rights nondiscrimination rules.
Recognized by her peers as a Martindale-Hubble “AV-Preeminent” (Top 1%) and “Top Rated Lawyer” with special recognition LexisNexis® Martindale-Hubbell® as “LEGAL LEADER™ Texas Top Rated Lawyer” in Health Care Law and Labor and Employment Law; as among the “Best Lawyers In Dallas” for her work in the fields of “Labor & Employment,” “Tax: Erisa & Employee Benefits,” “Health Care” and “Business and Commercial Law” by D Magazine, Cynthia Marcotte Stamer is a practicing attorney board certified in labor and employment law by the Texas Board of Legal Specialization and management consultant, author, public policy advocate and lecturer widely known for 30+ years of health industry and other management work, public policy leadership and advocacy, coaching, teachings, and publications. Ms. Stamer works with health industry and related businesses and their management, employee benefit plans, governments and other organizations deal with all aspects of human resources and workforce, internal controls and regulatory compliance, change management and other performance and operations management and compliance. Her experienced includes more than 20 years of experience advising and defending health industry and other organizations about disability and other civil rights discrimination law compliance and risk management. For additional information about Ms. Stamer, see here, e-mail her here or telephone Ms. Stamer at (214) 452-8297.
Solutions Law Press, Inc.™ provides human resources and employee benefit and other business risk management, legal compliance, management effectiveness and other coaching, tools and other resources, training and education on leadership, governance, human resources, employee benefits, data security and privacy, insurance, health care and other key compliance, risk management, internal controls and operational concerns. If you find this of interest, you also be interested reviewing some of our other Solutions Law Press, Inc.™ resources here. If you or someone else you know would like to receive future updates about developments on these and other concerns, please be sure that we have your current contact information including your preferred e-mail by creating your profile here.

References: v. 
 v. 
 v. 
 v. 
 v. 
 v.